Design and evaluation of a mucoadhesive therapeutic agent delivery system for postoperative chemotherapy in superficial bladder cancer.
The most common treatment method is known as the transurethral resection (TUR) for the therapy of bladder cancer. Unfortunately, because of the recurrency of the tumoral tissues after TUR the chemotherapy or immunotherapy should be performed. In these kind of therapies the pharmacotherapeutics are infused intravesically into the bladder after TUR periodically (i.e. upto 6--36 weeks, each week). But these therapies are having very big problems (i.e. disturbancy to patients, adjustment of the suitable dosage, loss of active agents without using etc.). An alternative approach can be proposed as to design a pharmacotherapeutic agent delivery system, which will supply the suitable dosage of the agent for a certain time period to solve those problems. In this study; the pharmacotherapeutic agent (i.e. Mytomycin-C) delivery system was prepared by using a mucoadhesive polymer (i.e. chitosan) in the form of cylindirical geometry to facilitate the insertion of the carrier for in vivo studies. The chitosan carriers were prepared by cross-linking during the solvent evaporation technique. In the preparation of the chitosan carriers the chitosan polymers with different molecular weights, different amounts of cross-linker (i.e. glutaraldehyde) and different amounts of pharmacotherapeutic agent were used to obtain desired attachment onto the bladder wall and optimum release rate of the agent. On the other hand because of the gelous structure of the chitosan, the swelling behaviour of the polymer was evaluated by gravimetric determinations in aqueous media periodically.
Eroğlu
Muzaffer
M
SSK Etlik Hospital, Ankara, Turkey.
Irmak
Ster
S
Acar
Abuzer
A
Denkbaş
Emir Baki
EB
D000269:Adhesives / Q000008:administration & dosage*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D001672:Biocompatible Materials / Q000008:administration & dosage / Q000737:chemistry; D002686:Chitin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000737:chemistry / Q000648:ultrastructure; D048271:Chitosan; D004337:Drug Carriers / Q000008:administration & dosage / Q000737:chemistry; D016503:Drug Delivery Systems / Q000295:instrumentation / Q000379:methods*; D004353:Drug Evaluation, Preclinical / Q000295:instrumentation / Q000379:methods*; D008855:Microscopy, Electron, Scanning; D016685:Mitomycin / Q000008:administration & dosage; D011182:Postoperative Care / Q000295:instrumentation / Q000379:methods*; D012756:Sheep; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000601:surgery
D000269:Adhesives; D000903:Antibiotics, Antineoplastic; D001672:Biocompatible Materials; D004337:Drug Carriers; D002686:Chitin; D016685:Mitomycin; D048271:Chitosan